FR2824478B1 - Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques - Google Patents
Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiquesInfo
- Publication number
- FR2824478B1 FR2824478B1 FR0204797A FR0204797A FR2824478B1 FR 2824478 B1 FR2824478 B1 FR 2824478B1 FR 0204797 A FR0204797 A FR 0204797A FR 0204797 A FR0204797 A FR 0204797A FR 2824478 B1 FR2824478 B1 FR 2824478B1
- Authority
- FR
- France
- Prior art keywords
- ncs
- development
- treatment
- therapeutic agents
- cns disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 1
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000002569 neuron Anatomy 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109536A EP1250931A1 (fr) | 2001-04-17 | 2001-04-17 | Nouvelle utilisation du neuronal calcium sensor-1 (ncs-1) pour le traitement de troubles du système nerveux central et pour le développement d'agents thérapeutiques |
EP01125816 | 2001-10-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2824478A1 FR2824478A1 (fr) | 2002-11-15 |
FR2824478B1 true FR2824478B1 (fr) | 2007-09-21 |
Family
ID=26076547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0204797A Expired - Fee Related FR2824478B1 (fr) | 2001-04-17 | 2002-04-17 | Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques |
Country Status (6)
Country | Link |
---|---|
US (1) | US7230155B2 (fr) |
JP (1) | JP2003040801A (fr) |
CH (1) | CH697372B1 (fr) |
DE (1) | DE10217066A1 (fr) |
FR (1) | FR2824478B1 (fr) |
GB (2) | GB2377635B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006043710A1 (ja) * | 2004-10-19 | 2008-05-22 | 株式会社リバース・プロテオミクス研究所 | 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法 |
WO2010054324A2 (fr) * | 2008-11-10 | 2010-05-14 | The Regents Of The University Of Colorado, A Body Corporate | Procédés pour traiter des états cliniques associés à l'activité lipoprotéine lipase |
EP3432911A1 (fr) | 2016-03-23 | 2019-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ciblage du capteur de calcium neuronal 1 pour le traitement du syndrome de wolfram |
CN107736311B (zh) * | 2017-11-21 | 2023-04-11 | 湖南卢氏环保科技有限公司 | 黑水虻养殖系统及控制方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH31213A (en) * | 1993-05-25 | 1998-05-05 | Daiichi Seiyaku Co | Drug for neuroprotection. |
US5624902A (en) * | 1995-06-07 | 1997-04-29 | Torrey Pines Institute For Molecular Studies | Peptide inhibitors of calmodulin |
US5981279A (en) * | 1995-11-09 | 1999-11-09 | Allegheny University Of The Health Sciences | Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation |
JP2001504328A (ja) | 1996-10-31 | 2001-04-03 | スミスクライン・ビーチャム・コーポレイション | 医薬上使用される化合物と結合するrna標的モチーフの特徴付けおよび選択の方法 |
US6165709A (en) | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
AU4080199A (en) | 1998-05-22 | 1999-12-13 | Incyte Pharmaceuticals, Inc. | Calmodulin related protein |
EP1082113A2 (fr) | 1998-05-26 | 2001-03-14 | Peter Louis Carlen | Compositions et procedes servant a soulager les fonctions mentales deficientes ou la perte de memoire et a limiter la duree de recuperation chez le mammifere anesthesie |
CN1287171A (zh) * | 1999-09-07 | 2001-03-14 | 复旦大学 | 人神经元钙传感蛋白及其编码序列、以及制法和用途 |
FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
-
2002
- 2002-04-12 GB GB0208525A patent/GB2377635B/en not_active Expired - Fee Related
- 2002-04-15 CH CH00627/02A patent/CH697372B1/de not_active IP Right Cessation
- 2002-04-17 US US10/124,334 patent/US7230155B2/en not_active Expired - Fee Related
- 2002-04-17 JP JP2002114976A patent/JP2003040801A/ja active Pending
- 2002-04-17 FR FR0204797A patent/FR2824478B1/fr not_active Expired - Fee Related
- 2002-04-17 DE DE10217066A patent/DE10217066A1/de not_active Withdrawn
-
2005
- 2005-04-20 GB GB0507998A patent/GB2411403A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
FR2824478A1 (fr) | 2002-11-15 |
GB0507998D0 (en) | 2005-05-25 |
GB2377635A (en) | 2003-01-22 |
CH697372B1 (de) | 2008-09-15 |
GB2377635B (en) | 2005-10-19 |
GB0208525D0 (en) | 2002-05-22 |
GB2411403A (en) | 2005-08-31 |
JP2003040801A (ja) | 2003-02-13 |
US20030159158A1 (en) | 2003-08-21 |
US7230155B2 (en) | 2007-06-12 |
DE10217066A1 (de) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2785521B1 (fr) | Dispositif de suspension pour le traitement de prolapsus et d'incontinences urinaires | |
FR2697162B1 (fr) | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. | |
DZ1716A1 (fr) | Méthode et mécanisme pour l'enlevement et le traitement des déchets. | |
MA26790A1 (fr) | Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie | |
FR2732357B1 (fr) | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose | |
FR13C0060I2 (fr) | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques | |
MA27027A1 (fr) | Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes | |
HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
DZ3027A1 (fr) | Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires. | |
MA26950A1 (fr) | Nouveaux retinoides pour le traitement de l'emphyseme | |
FR2815541B1 (fr) | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique | |
FR2705966B1 (fr) | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. | |
FR2741262B1 (fr) | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene | |
FR2824478B1 (fr) | Nouvelle utilisation du ncs-1(neuron specific calcium sensor-1)pour le traitement des troubles du snc et le developpement d'agents therapeutiques | |
FR2792835B3 (fr) | Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression | |
FR2764811B3 (fr) | Appareil pour le traitement physique des yeux | |
FR2717080B1 (fr) | Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales. | |
FR2808202B1 (fr) | Modification de la concentration ionique d'un fluide cervical pour le traitement de troubles neurologiques | |
FR2808894B1 (fr) | Procede et appareil photographique a usage unique pour empecher la reutilisation non-autorisee de l'appareil | |
FR2824742B1 (fr) | Dispositif de reeducation des vertiges et des troubles de l'equilibre | |
FR2756183B1 (fr) | Association d'huile et de peptides d'argan utile pour le traitement des troubles lies au vieillissement cutane | |
FR2803764B1 (fr) | Dispositif de reeducation a plateau tournant pour le traitement des vertiges et des troubles de l'equilibre | |
FR2792199B3 (fr) | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur | |
MA26908A1 (fr) | S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires | |
DZ3320A1 (fr) | Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20091231 |